Loading…
Adicet Bio, Inc. is projected to rise to $9.48 by 2027, a +4% move from its current price of $9.11. ACET is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $8.79 | $9.11 | $9.44 | -0.03% |
| Aug 6 | $8.66 | $9.11 | $9.57 | -0.05% |
| Aug 7 | $8.56 | $9.10 | $9.68 | -0.08% |
| Aug 8 | $8.48 | $9.10 | $9.77 | -0.11% |
| Aug 9 | $8.41 | $9.10 | $9.85 | -0.14% |
| Aug 10 | $8.34 | $9.10 | $9.92 | -0.16% |
| Aug 11 | $8.28 | $9.09 | $9.99 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.28 | $9.09 | $9.99 | -0.19% |
| Week 2 | $7.95 | $9.08 | $10.36 | -0.38% |
| Week 3 | $7.70 | $9.06 | $10.65 | -0.57% |
| Week 4 | $7.50 | $9.04 | $10.90 | -0.76% |
| Week 5 | $7.32 | $9.02 | $11.13 | -0.94% |
| Week 6 | $7.16 | $9.01 | $11.33 | -1.13% |
| Week 7 | $7.02 | $8.99 | $11.52 | -1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adicet Bio, Inc. is a clinical-stage biotechnology company that discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. Its lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
ACET trades at $9.06 per share. It has a market cap of $84.7M and a rank of 4017. The asset sits in the Healthcare category and is publicly traded under the ACET symbol.
A major floor 32.9% below — a decisive break under it would weaken the trend.
The nearest floor, 14.5% below — buyers have tended to step in here.
Price is pressing into resistance (1.5% away) — a breakout level to watch.
A major ceiling 11.7% above — clearing it would confirm fresh momentum.
Key ACET support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACET market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.55 | Buy | $8.70 | Buy |
| MA 10 | $8.35 | Buy | $8.53 | Buy |
| MA 20 | $8.53 | Buy | $8.46 | Buy |
| MA 50 | $8.29 | Buy | $8.29 | Buy |
| MA 100 | $7.88 | Buy | $8.23 | Buy |
| MA 200 | $8.55 | Buy | $8.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.40 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 105.71 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 4.95 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 0.12 | Buy |
| Ultimate (7,14,28) | 60.18 | Neutral |
| Momentum (10) | 0.99 | Buy |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 8.86 | Buy |
| ADX (14) | 10.51 | Neutral |
| ATR (14) | 0.28 | Info |
The sentiment is BULLISH. RSI(14) is 60, with a SMA50 of $8.26 and a SMA200 of $8.59. These moving averages frame a near-term picture where price action can be interpreted relative to established support and resistance levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.11 | $9.11 | $10.66 | 0% | Neutral | |
| $7.36 | $9.48 | $13.03 | +4% | Neutral | |
| $7.35 | $9.83 | $14.16 | +8% | Neutral | |
| $7.54 | $10.42 | $15.55 | +14% | Neutral | |
| $8.49 | $12.06 | $18.56 | +32% | Bullish | |
| $10.44 | $15.21 | $24.03 | +67% | Bullish | |
| $12.04 | $17.97 | $29.06 | +97% | Bullish | |
| $11.89 | $18.15 | $29.98 | +99% | Bullish | |
| $11.96 | $18.65 | $31.40 | +105% | Bullish | |
| $12.06 | $19.21 | $32.92 | +111% | Bullish | |
| $19.70 | $34.56 | $63.76 | +279% | Bullish | |
| $23.92 | $49.86 | $102.29 | +447% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $6.11 | $9.11 | $10.77 | +0.00% |
| September 2026 | $7.31 | $8.72 | $10.75 | -4.27% |
| October 2026 | $7.38 | $8.89 | $11.10 | +1.91% |
| November 2026 | $7.23 | $8.76 | $11.07 | -1.39% |
| December 2026 | $6.85 | $8.36 | $10.66 | -4.65% |
Click any year to see its month-by-month ACET forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACET price prediction for 2026 points to an average of $9.11 (low $6.11, high $10.66) — a potential gain of 0% on today's $9.11. Price action looks broadly range-bound.
In 2027, ACET is projected to trade between $7.36 and $13.03, averaging $9.48 — a potential gain of +4% from today's $9.11. That is up +4% on the projected 2026 average. A consolidation phase looks the most probable path here.
Adicet Bio, Inc.'s 2028 outlook centres on $9.83, within a $7.35 to $14.16 range. That is up +4% on the projected 2027 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2029, ACET could reach as high as $15.55, with a base case around $10.42 and support toward $7.54 — roughly +14% from $9.11. A consolidation phase looks the most probable path here.
Expect ACET to range from $8.49 to $18.56 through 2030. The $12.06 average target implies a +32% move from current prices. That is up +16% on the projected 2029 average. Momentum favours further upside here.
The ACET price prediction for 2031 points to an average of $15.21 (low $10.44, high $24.03) — a potential gain of +67% on today's $9.11. Buyers look set to stay in control over this stretch.
In 2032, ACET is projected to trade between $12.04 and $29.06, averaging $17.97 — a potential gain of +97% from today's $9.11. That is up +18% on the projected 2031 average. Momentum favours further upside here.
Adicet Bio, Inc.'s 2033 outlook centres on $18.15, within a $11.89 to $29.98 range. That is up +1% on the projected 2032 average. That marks a +99% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ACET could reach as high as $31.40, with a base case around $18.65 and support toward $11.96 — roughly +105% from $9.11. Momentum favours further upside here.
Expect ACET to range from $12.06 to $32.92 through 2035. The $19.21 average target implies a +111% move from current prices. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ACET price prediction for 2040 points to an average of $34.56 (low $19.70, high $63.76) — a potential gain of +279% on today's $9.11. Momentum favours further upside here.
In 2050, ACET is projected to trade between $23.92 and $102.29, averaging $49.86 — a potential gain of +447% from today's $9.11. That is up +44% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACET today (≈ 109.769484 ACET) could be worth
$5,472.72
+$4,472.72 (+447%) by 2050 · US Dollar
Based on the average projected ACET price of $49.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACETwould be worth at today's price.
$1,000 invested in ACET on Jul 31, 2025 (≈ 91.107873 ACET) would be worth
$829.99
-$170.01 (-17.0%) today · 0.83× · US Dollar
Based on a ACET entry price of $10.98 vs. today's $9.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.79 | $1,169.45 | +16.9% |
| 1 month ago | $8.62 | $1,056.84 | +5.7% |
| 3 months ago | $8.2 | $1,110.98 | +11.1% |
| 6 months ago | $7.98 | $1,141.6 | +14.2% |
| 1 year ago | $10.98 | $829.99 | -17.0% |
| All time (5.0y) ago | $113.92 | $79.97 | -92.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACET forecast.
Our base-case forecast reaches $18.00 around 2033.
Implied market cap at $18.00: $168.27M
Forecasts describe a multi-year growth path with the 2026 min $6.11, avg $9.06, max $10.55 and ROI 0, sentiment NEUTRAL. By 2030 the avg is $11.69 with a min of $8.17 and a max of $18.12, ROI 29 and sentiment BULLISH. 2031 shows avg $14.65, 2032 $17.33, 2033 $17.52, 2034 $17.79 and 2035 $18.33 with ROIs of 61.7, 91.3, 93.3, 96.4 and 102.3 respectively (all with BULLISH sentiment from 2030 onward).
The 2040 forecast places avg $32.74, max $61.10 and ROI 261.4 with a BULLISH tone, and the 2050 forecast places avg $46.45, max $96.56 and ROI 412.7 with a BULLISH tone.
Tap a question to reveal the answer.
Year 2030 avg $11.69; min $8.17; max $18.12; ROI 29; sentiment BULLISH.
Forecasts show an upward path with a 2030 avg of $11.69 and ROI 29, and a 2050 ROI of 412.7 with bullish sentiment by 2030 onward; 2026 is neutral. These are estimates, not guarantees.
Yes, the 2040 max is $61.10, while the 2040 avg is $32.74; reaching $50 by 2040 is within the forecasted range.
30-day range is $7.12-$11.52; support $7.79; resistance $9.25; RSI(14) 60; SMA50 $8.26; SMA200 $8.59; sentiment is BULLISH.
Lead product prulacabtagene leucel (prula-cel) is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20 for autoimmune diseases. It also develops ADI-212 targeting PSMA.
Adicet Bio, Inc. Community Discussion
0Share your Adicet Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.